Valuation: Insmed Incorporated

Market Cap 31.01B 28.27B 26.03B 23.7B 44.46B 2,873B 46.87B 317B 126B 1,566B 116B 114B 4,915B P/E 2026 *
-87.5x
P/E 2027 * 202x
Enterprise Value 30.49B 27.8B 25.6B 23.31B 43.72B 2,826B 46.09B 312B 124B 1,540B 114B 112B 4,833B EV / Sales 2026 *
16.4x
EV / Sales 2027 * 10.1x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-2.17%
1 week+16.65%
Current month+25.54%
1 month+47.73%
3 months+12.99%
6 months+30.97%
Current year-18.79%
1 week 118
Extreme 118
150
1 month 92.62
Extreme 92.625
150
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 11.31
Extreme 11.31
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Chief Tech/Sci/R&D Officer 62 2019-12-18
Chief Operating Officer 57 2019-11-13
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap. Importance
10/19/26 Free

Director

6,139 0.0028%
10/19/26 Free

Director

6,139 0.0028%
9/9/26 Sell

Director

-25,000 0.0114%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%+16.65%-29.21%+474.05% 31.01B
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-6.57%-12.37%+27.20%-14.67% 21.45B
Average -1.89%-2.33%+33.02%+156.27% 42B
Weighted average by Cap. -1.74%-2.39%+31.90%+142.39%

Financials

2026 *2027 *
Net sales 1.86B 1.7B 1.56B 1.42B 2.67B 172B 2.81B 19.03B 7.56B 94.01B 6.98B 6.84B 295B 2.99B 2.73B 2.51B 2.29B 4.29B 277B 4.52B 30.58B 12.14B 151B 11.22B 10.98B 474B
Net income -352M -321M -295M -269M -504M -32.58B -531M -3.59B -1.43B -17.76B -1.32B -1.29B -55.73B 164M 149M 138M 125M 235M 15.18B 248M 1.67B 665M 8.27B 615M 602M 25.96B
Net Debt -514M -469M -432M -393M -738M -47.67B -778M -5.26B -2.09B -25.99B -1.93B -1.89B -81.55B -949M -865M -797M -725M -1.36B -87.94B -1.43B -9.7B -3.85B -47.94B -3.56B -3.49B -150B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-11-20 US$141.33 -2.17% 6,216,094
26-11-19 US$144.46 +20.58% 14,410,442
26-11-18 US$119.80 -1.69% 1,944,159
26-11-17 US$121.86 -0.83% 2,398,022
26-11-16 US$122.88 +1.42% 2,233,188
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
141.33USD
Average target price
194.18USD
Spread / Average Target
+37.40%
  1. Stock Market
  2. Stocks
  3. INSM Stock